期刊文献+

血清HE4和CA125检测在卵巢癌诊断评估中的价值 被引量:9

原文传递
导出
摘要 目的探讨血清CA125和人附睾上皮分泌蛋白4(HE4)检测在卵巢癌诊断中的应用及其价值。方法 2011年6月至2012年5月因盆腔肿物行手术治疗的患者238例,根据手术后病理报告将分成卵巢恶性肿瘤组152例和盆腔良性肿瘤组86例,另选健康女性61例为对照组,检测3组血清HE4和CA125水平。结果卵巢癌患者血清HE4和CA125水平均明显高于盆腔良性肿瘤和健康对照者(P均<0.01)。单独检测血清HE4水平对卵巢癌诊断的特异性(91.9%)明显高于CA125(72.1%,P<0.05);单独检测血清CA125对卵巢癌诊断的敏感性(79.6%)明显高于HE4(54.6%,P<0.01);二项联合检测对卵巢癌诊断的敏感性(87.5%)和准确率(80.1%)显著高于HE4单独检测(54.6%和68.1%,P均<0.01)。结论在卵巢癌的诊断上,CA125有较高的灵敏性,特异性较差;HE4有较高的特异性,灵敏性稍低;两者联合检测有利于提高诊断的敏感性和准确率。
出处 《中国临床研究》 CAS 2015年第2期251-252,257,共3页 Chinese Journal of Clinical Research
  • 相关文献

参考文献15

  • 1Badgwel D, Bast RC Jr. Early detection of ovarian cancer [ J]. DisMarkers,2007,23(5 -6) :397 -410.
  • 2陈丽梅,章琼,刘琦,管群.HE4—一种新的卵巢上皮性癌肿瘤标记物的研究进展[J].现代妇产科进展,2010,19(1):66-68. 被引量:7
  • 3Riedinger J,Bonnetain F,Basuyau J,et al. Change in CAI25 levelsafter the frist cycle of induction chemotherapy is an independent pre-dictor of epithelial ovarian tumor outcome[ J]. Ann Oncol,2007,18(5):881 -885.
  • 4Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al. The HE4(WFDC2 ) protein is a biomarker for ovarian carcinoma [ J ] . CancerRes,2003,63(13) :3695 -3700.
  • 5Drapkin R,Von Horsten HH,Lin Y,et al. Human epididymis protein4( HE4) is a secreted glycoprotein that is overexpressed by serousand endometrioil ovarian carcinomas[ J]. Cancer Res,2005 ,65(6):2162 -2169.
  • 6Galgano MT, Hampton GM, Frierson HF Jr. Comprehersive analysisof HE4 expression in normal and malignant human tissusef J]. ModPathol,2006,19(6) :847 -853.
  • 7韩文明.HE4和CA125联合检测在卵巢癌诊断中的应用价值[J].国际检验医学杂志,2012,33(14):1757-1758. 被引量:22
  • 8刘琛姝,王永莉,潘玉韵.联合检测CA125、HE4和RBP4对预测上皮性卵巢癌的临床价值评价[J].热带医学杂志,2012,12(10):1233-1236. 被引量:7
  • 9Lorkova L,Pospisilova J,Lacheta J,et al. Decreased concentrations ofretinol-hinding protein 4 in sera of epithelial ovarian cancer patients :.a potential biomarker identified by proteomics[ J]. Oncol Rep,2012, 27 (2) :318 -324.
  • 10Rosen DG,Wang L, Atkinson JN,et al. Potential markers that com-plement experssion of CA125 in epithelial ovarian cancer[ J] . Gyne-col Oncol’2005 ’ 99 (1) :267 - 277.

二级参考文献67

  • 1杨永彬,徐伟,陈建利,万小平.卵巢癌肿瘤标志物研究进展[J].国外医学(妇产科学分册),2004,31(4):229-232. 被引量:24
  • 2李巍,崔恒,冯捷,李艺.卵巢癌诊断的研究进展[J].中华妇产科杂志,2005,40(7):496-498. 被引量:74
  • 3黄坚,石一复.不同部位子宫内膜异位症与血清CA125水平的关系[J].现代妇产科进展,2006,15(1):39-41. 被引量:22
  • 4Pickle LW,Hao Y, Jemal A, et al. A new method of estimating United States and state-level cancer incidence counts for the current calendar year [ J ]. CA Cancer J Clin, 2007,57 : 30-42.
  • 5Drapkin R, Lin Y, Mok SC, et al. Human epididymis prorein 4( HFA ) is a secreted glycoprotein that is over expressed by serougt and endometrioid ovarian carcinomas [ J]. Cancer Res ,2005,65:2162-2169.
  • 6Bast Jr RC. Status of tumor markers in ovarian cancer screening [ J ]. J Clin Oncol.2003,21 : 200-205.
  • 7Piver MS, Baker TR, Driscoll DL. Lack of substantial five year disease-free survival by primary aggressive surgery and cisplatin-based chemotherapy or by salvage intraperitoneal cisplatin-based chemotherapy [ J ]. Eur J Gynaecol Oncol, 1990,11:243-250.
  • 8Hellstrom I, Raycraft J, Schummer M, et al. The HFA (WFDC2) protein is a biomarker for ovarian carcinoma [ J]. Cancer Res ,2003,63:3695-3700.
  • 9Kirchhoff C, Habben I, Ivell R, et al. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors [ J ]. Biol Reprod, 1991,45:350-357.
  • 10Kirchhoff C. Molecular characterization of epididymal proteins[ J]. Rev Reprod, 1998,3:86-95.

共引文献75

同被引文献102

  • 1宋颖,朱晓飞.HE4和CA125联合检测在卵巢癌中临床应用价值[J].临床检验杂志(电子版),2014,3(2):625-627. 被引量:2
  • 2Karve TM, Preet A, Sneed R, et al. BRCA1 regulates fol- listatin function in ovarian cancer and human ovarian surface epithelial cells [jj. PLoS One, 2012, 7 (6): e37697.
  • 3Riedinger J, Bonnetain F, Basuyau J, et al. Change in CA125 levels after the firet cycle of induction chemotherapy is an inde- pendent predictor of epithelial ovarian tumor outcome [ J ].AnnOncol, 2007, 18 (5): 881-885.
  • 4Wakatsuki M, Shintani Y, Abe M, et al. Immunoradiometric assay for follistatin: Serum Immunoreactive follistatin level in normal adult and pregnant women [ J ]. Clin Endocrinol Metab, 1996, 81 (2): 630.
  • 5Liu ZH, Shintani Y, Sakamoto Y, et al. Effects of LHRH, FSH and activin A on follistatin secretion from cultured rat an- terior pituitary cells [J]. Endocr J, 1996, 43 (3) : 321.
  • 6Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial [J]. JAMA, 2010, 305 (22): 2295.
  • 7Lawicki S, Bedkowska GE, Gaottta SE, et al. The plasma concentration of VEGF, HE4 and A125 as a new biomark- ers panel in different stages and sub-types of epithelial ovari- an tumors [J]. J Ovarian Res, 2013, 6 (1): 45.
  • 8梁美蓉,曾四元,王素兰,等.人附泉蛋白4联合CAl25检测在卵巢良恶性肿瘤诊断中的应用价值[J].中华临床医师杂志,2013,7(20):9148-9152.
  • 9Chuang Chen,Liangdong Chen,Zhiling Zhang,Yan Li.Advances in the application of quantum dots in tumor markers investigation[J].The Chinese-German Journal of Clinical Oncology,2008,7(3):179-184. 被引量:6
  • 10卢仁泉,郭林,胡娟.人附睾上皮分泌蛋白4在卵巢癌诊治中的应用价值[J].中华检验医学杂志,2009,32(12):1379-1383. 被引量:34

引证文献9

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部